In 2023, the pace of technological innovation in the field of life and health is strong and solid. China has officially implemented "Class B and Class B management" for COVID-19 infection. The first domestic ECMO product has been approved for marketing. Breakthroughs have been made in the research of several nervous system diseases. The human immune system has a high-definition "ethnic group" portrait, and the latest national medical insurance catalog has added 126 drugs... Scientific and technological forces are driving the construction of a healthy China into the "fast lane". With the continuous improvement of medical policies, the continuous progress of medical technology, and the continuous improvement of medical standards, people's lives and health will be better guaranteed. To improve the accessibility of advanced medical equipment, the first domestic ECMO product was approved for marketing from little known to widely known. The extracorporeal membrane oxygenation (ECMO) equipment, commonly known as "artificial heart lung", repeatedly appeared to rescue people in distress during the COVID-19 epidemic. The data shows that the development of ECMO involves multiple important technologies and components. The most core of them are membrane lungs and blood pumps, which respectively play a role in replacing the lungs and heart. One of the difficulties in ECMO research and development is how to provide the required circulating flow and gas exchange capacity for patients in a long-term stable manner, while minimizing the damage of the extracorporeal circulation system to the blood. The requirements for biocompatible materials, system integrity, and manufacturing processes are very high. On January 4th, China's first domestically produced ECMO was approved for launch. It is less than three years since the Ministry of Industry and Information Technology urgently launched the "ECMO Special Research Task" in early 2020. Zheng Hairong, an academician of the CAS Member, said at the press conference for the approval and listing of the first nationally produced ECMO complete machine that the major ECMO projects have achieved innovative results in the research and development of key technologies and components. Among them, the magnetic levitation centrifugal pump has technical advantages such as small pre charge, high pumping efficiency, long service life, and minimal blood cell damage through fluid dynamics design and impeller process iteration. In addition, the magnetic levitation centrifugal pump can effectively reduce the damage of the extracorporeal circulation system to the blood. The relevant research results indicate that compared with mechanical bearing centrifugal pumps, all magnetic levitation centrifugal pumps cause less damage to blood cells. After rescue trials in 11 hospitals across the country and 37 critically ill patients, the performance indicators of domestically produced ECMO have reached the advanced level of similar products. As of now, the National Medical Products Administration has approved the launch of three domestically produced ECMO products, and their overall performance and indicators have basically reached the level of similar international products. Among them, the research and development team for the second domestically produced ECMO Huisheng I model includes 18 institutes of China Aerospace Science and Technology Group First Hospital, Beijing Union Medical College Hospital, and other units. The highly integrated and lightweight "aerospace genes" make the total weight of the Huisheng I ECMO less than 7.5 kilograms, about one-third of the weight of similar foreign products, which can better meet the needs of emergency treatment and transportation for critically ill patients. The successive approval and launch of domestically produced ECMO products have improved the accessibility of advanced life support equipment in China. Overall epidemic prevention and control and economic and social development China implemented "Class B and Class B management" for COVID-19 infection. On January 7, the Comprehensive Group of the Joint Prevention and Control Mechanism of the State Council issued the "novel coronavirus Infection Prevention and Control Plan (10th Edition)", and "novel coronavirus Pneumonia" was renamed "novel coronavirus Infection". The 10th edition of the prevention and control plan continues